Which stocks are experiencing notable movement on Tuesday? Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive.
Tech Stocks Drop, Palantir Plunges Over 8%: What's Moving Markets Tuesday? Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally.
These stocks are moving in today's session Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Why Novo Nordisk Stock Popped Today For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.
Why Viking Therapeutics Stock Crashed Today Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable?
Let's uncover which stocks are experiencing notable gaps during today's session. The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo.
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735.
Tuesday's pre-market session: top gainers and losers Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Stock Market Today: S&P 500 Slips, Dow Futures Rise—Intel, Palo Alto, Home Depot In Focus U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed.
Predicting the Next Rule Breaker Buyout Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?
Why Viking Therapeutics Stock Zoomed 5% Higher Today The company is a front-runner in the race to develop an orally administered weight loss drug.
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback.
The 3 Things That Matter for Viking Therapeutics Now Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
